Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23

[1]  G. Mortier,et al.  Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium , 2021, Frontiers in Endocrinology.

[2]  R. Kumar,et al.  Burosumab for the Treatment of Tumor‐Induced Osteomalacia , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  Yutaka Takahashi,et al.  Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia , 2020, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  J. Ji,et al.  A Comparison Study of Vitamin D Deficiency among Older Adults in China and the United States , 2019, Scientific Reports.

[5]  T. Matsushita,et al.  Insufficiency and deficiency of vitamin D in elderly patients with fragility fractures of the hip in the Japanese population , 2019, Journal of orthopaedic surgery.

[6]  R. Eastell,et al.  Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period , 2019, Calcified Tissue International.

[7]  F. Glorieux,et al.  Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial , 2019, The Lancet.

[8]  J. S. San Martin,et al.  A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults With X‐Linked Hypophosphatemia: Week 24 Primary Analysis , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  J. S. San Martin,et al.  Burosumab Therapy in Children with X‐Linked Hypophosphatemia , 2018, The New England journal of medicine.

[10]  P. Chanson,et al.  Evaluation of a New Fully Automated Assay for Plasma Intact FGF23 , 2017, Calcified Tissue International.

[11]  D. Kang,et al.  Collaborative derivation of reference intervals for major clinical laboratory tests in Japan , 2016, Annals of clinical biochemistry.

[12]  R. Pereira,et al.  FGF23-Associated Tumor-Induced Osteomalacia in a Patient With Small Cell Carcinoma , 2016, International journal of surgical pathology.

[13]  Toshio Matsumoto,et al.  Pathogenesis and diagnostic criteria for rickets and osteomalacia—proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society , 2015, Journal of Bone and Mineral Metabolism.

[14]  J. Klastersky,et al.  Tumour-associated osteomalacia and hypoglycaemia in a patient with prostate cancer: is Klotho involved? , 2014, BMJ Case Reports.

[15]  S. N. Narla,et al.  25-Hydroxyvitamin D: analysis and clinical application. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[16]  J. Epstein,et al.  Small cell carcinoma of the prostate , 2014, Nature Reviews Urology.

[17]  C. Rosen,et al.  Bone as an endocrine organ. , 2012, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[18]  P. Hoff,et al.  Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition , 2012, Supportive Care in Cancer.

[19]  T. Fujita,et al.  Evaluation of a new automated chemiluminescence immunoassay for FGF23 , 2012, Journal of Bone and Mineral Metabolism.

[20]  J. Body,et al.  Hypophosphatemia Related to Paraneoplastic Cushing Syndrome in Prostate Cancer: Cure After Bilateral Adrenalectomy , 2011, Calcified Tissue International.

[21]  T. Martin,et al.  Bone as an endocrine organ , 2009, Trends in Endocrinology & Metabolism.

[22]  O. Franco,et al.  Plasma 25-Hydroxyvitamin D Concentration and Metabolic Syndrome Among Middle-Aged and Elderly Chinese Individuals , 2009, Diabetes Care.

[23]  I. Endo,et al.  Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. , 2008, Bone.

[24]  P. Rao,et al.  Elevated fibroblast growth factor 23 in a patient with metastatic prostate cancer and hypophosphatemia. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  S. Takeda,et al.  Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans , 2007, Journal of Bone and Mineral Metabolism.

[26]  S. Fukumoto,et al.  FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23. , 2007, Bone.

[27]  M. Econs,et al.  Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. , 2006, The Journal of clinical endocrinology and metabolism.

[28]  D. Jackman,et al.  Small-cell lung cancer , 2005, The Lancet.

[29]  R. Rizzoli,et al.  Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. , 2005, The Journal of clinical endocrinology and metabolism.

[30]  S. Fukumoto,et al.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.

[31]  K. White,et al.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.

[32]  Y. Takeuchi,et al.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. , 2002, The Journal of clinical endocrinology and metabolism.

[33]  C. McMurtry,et al.  Oncogenic Osteomalacia Associated with Metastatic Prostate Carcinoma: Case Report and Review of the Literature , 1993, Journal of the American Geriatrics Society.

[34]  F. Johnson,et al.  Small cell carcinoma of the prostate , 1991, Cancer.

[35]  G. Kalemkerian,et al.  Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.

[36]  M. Haussler,et al.  Hypophosphatemic osteomalacia: association with prostatic carcinoma. , 1980, Annals of internal medicine.

[37]  D. Lirenman,et al.  HYPOCALCEMIA AND HYPOPHOSPHATEMIA ACCOMPANYING OSTEOBLASTIC METASTASES. , 1964, The Journal of clinical endocrinology and metabolism.

[38]  G. L. À. Lycklama à Nijeholt,et al.  Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management. , 2005, Bone.

[39]  Y. Takeuchi,et al.  Comparison of two assays for fibroblast growth factor (FGF)-23 , 2005, Journal of Bone and Mineral Metabolism.

[40]  H. Nakahama,et al.  Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. , 1995, Urologia internationalis.

[41]  U. Kabadi.  Osteomalacia associated with prostatic cancer and osteoblastic metastases. , 1983, Urology.